



ASX ANNOUNCEMENT

8 November 2019

CardieX Appoints New Chinese Distributor to Drive Growth and New Market Opportunities

CardieX (ASX:CDX, the "Company") is pleased to announce that as of October 1, 2019, the Company's ATCOR medical device division has officially partnered with Beijing Auden Technologies Limited ("Auden" - www.auden-china.com) as its new national distributor in China. Auden will further commercialization efforts for ATCOR's non-invasive central blood pressure (NcBP) monitoring technology in public and private hospital channels as well as sports medicine institutions in the Greater China region, including mainland China, Hong Kong and Macau.

With substantial experience in clinical education and strategic marketing of cardiovascular health technologies, Auden has made significant inroads into top-tier Level 3A hospitals as a professional medical technology distributor with strong cardiology focus. Covering the Chinese healthcare industry since 2009, Auden has represented several leading medical technology innovators in hypertension, diabetes, and sleep health, including Omron Healthcare and Itamar Medical.

Some of the medical institutions that Auden collaborates with include: Peking Union Medical College Hospital, Chinese Academy of Medical Sciences Fuwai Hospital, People's Liberation Army General Hospital, Peking University First Hospital, Peking University People's Hospital, Peking University Third Hospital, Beijing Chaoyang Hospital, First Affiliated Hospital of Sun Yat-sen University, Southern Medical University Nanfang Hospital, Xiangya Hospital, and many others across China.

With this new partnership, the founders of Auden are seeking to further their cardiology distribution business with a focused commercial strategy around ATCOR's XCEL system as its primary portfolio offering.

Commenting on the partnership, CardieX's VP of Corporate Development ZiHan Lin stated: *"With this renewed focus on XCEL and prior experience in other chronic illness technologies, we believe Auden is well-positioned to drive ATCOR's long-term growth plans in the Chinese market. This also represents a material step forward as we look to broaden our market penetration in China for our roadmap of new products and services"*.

Garry Zhang, CEO of Auden commented: *"ATCOR provides a personalized and precise solution for hypertensive patients. Through earnest collaboration between Auden and ATCOR, I believe we can dramatically increase the adoption of ATCOR's technology, especially due to its strategic alignment with China's nationwide advancement of the "Healthy China 2030" initiative"*.



ATCOR

Personalized and precise hypertension management

SphygmoCor®XCEL is the industry standard for noninvasive central blood pressure (NcBP), a better way to individualize treatment for cardiovascular disease.

提供高血压及心脏疾病的个性化精准管理



公司概况 COMPANY

关注血管病变，监测心脏健康
Focus on Vascular Disease, Monitor Cardiovascular Health

澳德亨公司创立于2009年，旨在将全球顶尖的医疗器械产品引入中国，

为临床医生及患者提供最先进的医疗技术及产品

“用心服务、用心靠近，关注血管病变，全程监测心脏健康”；是公司的定位也是一直以来着力和致力的方向。



[ATCOR as featured on the home page of Auden’s Chinese website www.auden-china.com]

For more information please contact:

Investor Relations

Peter Taylor – NWR Communications

peter@nwrcommunications.com.au

About CardieX

CardieX is a global health technology company that develops digital and device based solutions for large-scale population health disorders. The Company’s XCEL device is the world leader in measuring “central blood pressure” (cBP) which is considered essential for the management of hypertension and related cardiovascular disorders. XCEL was developed and is marketed by CardieX’s 100% subsidiary, ATCOR.

CardieX also has a joint venture partnership with Blumio, Inc in Silicon Valley for the development of a radar-based blood pressure sensor incorporating CardieX technology. In November 2018 CardieX entered into an agreement with inHealth Medical, Inc allowing CardieX to acquire up to 50.5% of inHealth by way of a convertible note.

In September, 2019 the Company signed an agreement with Mobvoi, Google’s partner in China, for the co-development of new wearable technologies and devices based on Mobvoi’s smart watch products.